{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:04:02Z","timestamp":1791993842858,"version":"4.4.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI105204"],"award-info":[{"award-number":["R01 AI105204"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Portuguese Foundation for Science and Technology","award":["PD\/BD\/105847\/2014"],"award-info":[{"award-number":["PD\/BD\/105847\/2014"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ebola virus (EBOV) is a highly lethal member of the Filoviridae family associated with human hemorrhagic disease. Despite being a sporadic disease, it caused a large outbreak in 2014\u20132016 in West Africa and another outbreak recently in the Democratic Republic of Congo. Several vaccine candidates are currently in preclinical and clinical studies but none are stable without cold chain storage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used preservation by vaporization (PBV), a novel processing technology to heat-stabilize FiloRab1 (inactivated rabies-based Ebola vaccine), a candidate Ebola vaccine, and stored the vials at temperatures ranging from 4\u00b0C to 50\u00b0C for 10 days to 12 months. We immunized Syrian hamsters with the best long-term stable FiloRab1 PBV vaccines and challenged them with rabies virus (RABV).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Syrian hamsters immunized with FiloRab1 PBV\u2013processed vaccines stored at temperatures of 4\u00b0C and 37\u00b0C for 6 months, and at 50\u00b0C for 2 weeks, seroconverted against both RABV-G and EBOV-GP. Notably, all of the FiloRab1 PBV vaccines proved to be 100% effective in a RABV challenge model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We successfully demonstrated that the FiloRab1 PBV vaccines are stable and efficacious for up to 6 months when stored at temperatures ranging from 4\u00b0C to 37\u00b0C and for up to 2 weeks at 50\u00b0C.<\/jats:p><\/jats:sec>","DOI":"10.1093\/infdis\/jiz332","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T19:09:19Z","timestamp":1562872159000},"page":"1521-1528","source":"Crossref","is-referenced-by-count":16,"title":["Inactivated Rabies Virus\u2013Based Ebola Vaccine Preserved by Vaporization Is Heat-Stable and Immunogenic Against Ebola and Protects Against Rabies Challenge"],"prefix":"10.1093","volume":"220","author":[{"given":"Drishya","family":"Kurup","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine R","family":"Fisher","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd G","family":"Smith","sequence":"additional","affiliation":[{"name":"National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Abreu-Mota","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[{"name":"National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix R","family":"Jackson","sequence":"additional","affiliation":[{"name":"National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Gallardo-Romero","sequence":"additional","affiliation":[{"name":"National Center for Emerging and Zoonotic Infectious Diseases, Division of High-Consequence Pathogens and Pathology, Poxvirus and Rabies Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Franka","sequence":"additional","affiliation":[{"name":"Center for Global Health, Global Immunization Division, Polio Eradication Branch, CDC, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Bronshtein","sequence":"additional","affiliation":[{"name":"Universal Stabilization Technologies Inc, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias J","family":"Schnell","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania"},{"name":"Jefferson Vaccine Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,8,3]]},"reference":[{"key":"2019092610231327000_CIT0001","volume-title":"Ebola virus disease","author":"Centers for Disease Control and Prevention"},{"key":"2019092610231327000_CIT0002","volume-title":"Workshop on expanded access to experimental Ebola vaccines during outbreaks","author":"World Health Organization"},{"key":"2019092610231327000_CIT0003","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/infdis\/jix190","article-title":"Progress in Ebola virus vaccine development","volume":"215","author":"Schnell","year":"2017","journal-title":"J Infect Dis"},{"key":"2019092610231327000_CIT0004","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/S1473-3099(17)30541-8","article-title":"Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report","volume":"17","author":"Gsell","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019092610231327000_CIT0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2019092610231327000_CIT0006","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u2206G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019092610231327000_CIT0007","volume-title":"Ebola vaccines\u2014background paper for SAGE deliberations","author":"World Health Organization"},{"key":"2019092610231327000_CIT0008","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(18)30560-9","article-title":"Questionable efficacy of the rVSV-ZEBOV Ebola vaccine","volume":"391","author":"Metzger","year":"2018","journal-title":"Lancet"},{"key":"2019092610231327000_CIT0009","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(18)30559-2","article-title":"Questionable efficacy of the rVSV-ZEBOV Ebola vaccine\u2014authors\u2019 reply","volume":"391","author":"Longini","year":"2018","journal-title":"Lancet"},{"key":"2019092610231327000_CIT0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.vetmic.2012.08.023","article-title":"Stability and inactivation of vesicular stomatitis virus, a prototype rhabdovirus","volume":"162","author":"Zimmer","year":"2013","journal-title":"Vet Microbiol"},{"key":"2019092610231327000_CIT0011","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/infdis\/jiv532","article-title":"Stability of a vesicular stomatitis virus-vectored Ebola vaccine","volume":"213","author":"Arnemo","year":"2016","journal-title":"J Infect Dis"},{"key":"2019092610231327000_CIT0012","volume-title":"Summary of stability data for licensed vaccines","author":"PATH Vaccine and Pharmaceutical Technologies Group"},{"key":"2019092610231327000_CIT0013","volume-title":"Preservation by vaporization. Patent number US 9,469,835 B2","author":"Bronshtein","year":"2016"},{"key":"2019092610231327000_CIT0014","doi-asserted-by":"crossref","first-page":"752","DOI":"10.2460\/ajvr.78.6.752","article-title":"Assessment of the immunogenicity of rabies vaccine preserved by vaporization and delivered to the duodenal mucosa of gray foxes (Urocyon cinereoargenteus)","volume":"78","author":"Smith","year":"2017","journal-title":"Am J Vet Res"},{"key":"2019092610231327000_CIT0015","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.vaccine.2015.03.025","article-title":"Rabies vaccine preserved by vaporization is thermostable and immunogenic","volume":"33","author":"Smith","year":"2015","journal-title":"Vaccine"},{"key":"2019092610231327000_CIT0016","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","article-title":"Preclinical development of inactivated rabies virus-based polyvalent vaccine against rabies and filoviruses","volume":"212","author":"Willet","year":"2015","journal-title":"J Infect Dis"},{"key":"2019092610231327000_CIT0017","doi-asserted-by":"crossref","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","article-title":"Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine","volume":"9","author":"Blaney","year":"2013","journal-title":"PLoS Pathog"},{"key":"2019092610231327000_CIT0018","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An inactivated rabies virus-based Ebola vaccine, FILORAB1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models","volume":"214","author":"Johnson","year":"2016","journal-title":"J Infect Dis"},{"key":"2019092610231327000_CIT0019","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1128\/IAI.16.3.915-919.1977","article-title":"Antibody response to rabies virus in Syrian hamsters","volume":"16","author":"Coe","year":"1977","journal-title":"Infect Immun"},{"key":"2019092610231327000_CIT0020","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.1016\/j.vaccine.2012.07.073","article-title":"Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein","volume":"30","author":"Papaneri","year":"2012","journal-title":"Vaccine"},{"key":"2019092610231327000_CIT0021","first-page":"88","article-title":"The fluorescent antibody test","volume-title":"Laboratory techniques in rabies","author":"Dean","year":"1996","edition":"4th ed"},{"key":"2019092610231327000_CIT0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-12-801919-1.00017-8","article-title":"The rapid fluorescent focus inhibition test","volume-title":"Current laboratory techniques in rabies diagnosis, research and prevention","author":"Yager","year":"2015"},{"key":"2019092610231327000_CIT0023","volume-title":"WHO expert consultation on rabies-second report","author":"World Health Organization"},{"key":"2019092610231327000_CIT0024","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejpb.2018.06.001","article-title":"Stability and suitability for storage and distribution of Ad26.ZEBOV\/MVA-BN\u00ae-Filo heterologous prime-boost Ebola vaccine","volume":"129","author":"Capelle","year":"2018","journal-title":"Eur J Pharm Biopharm"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiz332\/29095019\/jiz332.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/9\/1521\/30061829\/jiz332.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T23:16:17Z","timestamp":1610406977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/220\/9\/1521\/5543203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,3]]},"references-count":24,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,8,3]]},"published-print":{"date-parts":[[2019,9,26]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz332","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,8,3]]}}}